A Crossover Design for Comparative Efficacy: A 36-Week Randomized Trial of Bevacizumab and Ranibizumab for Diabetic Macular Edema.
about
Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.Anti-VEGF treatment of diabetic macular edema in clinical practice: effectiveness and patterns of use (ECHO Study Report 1).Platform-Independent Cirrus and Spectralis Thickness Measurements in Eyes with Diabetic Macular Edema Using Fully Automated SoftwareInvestigating the Fractal Dimension of the Foveal Microvasculature in Relation to the Morphology of the Foveal Avascular Zone and to the Macular Circulation in Patients With Type 2 Diabetes Mellitus
P2860
A Crossover Design for Comparative Efficacy: A 36-Week Randomized Trial of Bevacizumab and Ranibizumab for Diabetic Macular Edema.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 February 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A Crossover Design for Compara ...... ab for Diabetic Macular Edema.
@en
A Crossover Design for Compara ...... ab for Diabetic Macular Edema.
@nl
type
label
A Crossover Design for Compara ...... ab for Diabetic Macular Edema.
@en
A Crossover Design for Compara ...... ab for Diabetic Macular Edema.
@nl
prefLabel
A Crossover Design for Compara ...... ab for Diabetic Macular Edema.
@en
A Crossover Design for Compara ...... ab for Diabetic Macular Edema.
@nl
P2093
P2860
P1433
P1476
A Crossover Design for Compara ...... ab for Diabetic Macular Edema.
@en
P2093
Catherine A Cukras
Catherine B Meyerle
Clare Bailey
Darby J S Thompson
Erin K Loken
Frederick L Ferris
Glenn J Jaffe
Henry E Wiley
Richard W J Lee
P2860
P304
P356
10.1016/J.OPHTHA.2015.11.021
P50
P577
2016-02-10T00:00:00Z